thalidomide has been researched along with Leukemia, Smoldering in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the efficiency and side-effects of the combination of cyclosporine A (CsA) and thalidomide in patients with myelodysplastic syndromes (MDS)." | 7.76 | [Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes]. ( Hao, YS; Liu, KQ; Qin, TJ; Xiao, ZJ; Xu, ZF; Zhang, Y, 2010) |
| "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA." | 7.71 | Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002) |
| "Oral thalidomide was then started at 100 mg/day (with the dose escalated up to 300 mg/day if well tolerated) for up to 1 year." | 6.72 | Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. ( Billmeier, J; Galili, N; Gohar, S; Lisak, L; Mumtaz, M; Pervaiz, H; Raza, A; Wahid, K, 2006) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 6.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| "To explore the efficiency and side-effects of the combination of cyclosporine A (CsA) and thalidomide in patients with myelodysplastic syndromes (MDS)." | 3.76 | [Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes]. ( Hao, YS; Liu, KQ; Qin, TJ; Xiao, ZJ; Xu, ZF; Zhang, Y, 2010) |
| "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA." | 3.71 | Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002) |
| "Oral thalidomide was then started at 100 mg/day (with the dose escalated up to 300 mg/day if well tolerated) for up to 1 year." | 2.72 | Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. ( Billmeier, J; Galili, N; Gohar, S; Lisak, L; Mumtaz, M; Pervaiz, H; Raza, A; Wahid, K, 2006) |
| "We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 2.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manabe, M | 1 |
| Okita, J | 1 |
| Tarakuwa, T | 1 |
| Harada, N | 1 |
| Aoyama, Y | 1 |
| Kumura, T | 1 |
| Ohta, T | 1 |
| Furukawa, Y | 1 |
| Mugitani, A | 1 |
| Möller, I | 1 |
| Blum, S | 1 |
| Gattermann, N | 2 |
| Haas, R | 2 |
| Habersang, K | 1 |
| Germing, U | 2 |
| Kuendgen, A | 1 |
| Sekeres, MA | 1 |
| O'Keefe, C | 1 |
| List, AF | 1 |
| Paulic, K | 1 |
| Afable, M | 1 |
| Englehaupt, R | 1 |
| Maciejewski, JP | 1 |
| Xu, ZF | 1 |
| Qin, TJ | 1 |
| Zhang, Y | 1 |
| Liu, KQ | 1 |
| Hao, YS | 1 |
| Xiao, ZJ | 1 |
| Douet-Guilbert, N | 1 |
| De Braekeleer, E | 1 |
| Basinko, A | 1 |
| Morel, F | 1 |
| Le Bris, MJ | 1 |
| De Braekeleer, M | 1 |
| Musto, P | 1 |
| Falcone, A | 1 |
| Sanpaolo, G | 1 |
| Bisceglia, M | 1 |
| Matera, R | 1 |
| Carella, AM | 1 |
| Raza, A | 1 |
| Lisak, L | 1 |
| Billmeier, J | 1 |
| Pervaiz, H | 1 |
| Mumtaz, M | 1 |
| Gohar, S | 1 |
| Wahid, K | 1 |
| Galili, N | 1 |
| Strupp, C | 1 |
| Aivado, M | 1 |
| Misgeld, E | 1 |
| Zorat, F | 1 |
| Pozzato, G | 1 |
2 reviews available for thalidomide and Leukemia, Smoldering
| Article | Year |
|---|---|
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
Thalidomide in myelodysplastic syndromes.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Abe | 2002 |
2 trials available for thalidomide and Leukemia, Smoldering
| Article | Year |
|---|---|
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Lenalidomide; Male; Middle Age | 2011 |
Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Dose-Response Relationship, Drug; Drug Administrati | 2006 |
5 other studies available for thalidomide and Leukemia, Smoldering
| Article | Year |
|---|---|
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-) | 2009 |
[Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes].
Topics: Anemia, Refractory, with Excess of Blasts; Cyclosporine; Humans; Myelodysplastic Syndromes; Thalidom | 2010 |
Distinct clonal deletions of the long arm of chromosome 5 in a patient with myelodysplastic syndrome.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfus | 2012 |
Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Combined Moda | 2002 |
Thalidomide for the treatment of patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transf | 2002 |